Loading...
Market
Will BEAM-101 outperform Reni-cel and Casgevy in clinical trials by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Clinical trial results published in medical journals or conferences
Story
Beam Therapeutics' BEAM-101 Shows Superior Results at ASH 2024, Stock Rises
Dec 9, 2024, 12:57 PM
Beam Therapeutics Inc. has reported promising clinical data for its sickle cell gene therapy, BEAM-101, at the American Society of Hematology (ASH) 2024 conference. The therapy has shown an average of 64-65% fetal hemoglobin (HbF) levels in patients, significantly higher than its competitors Reni-cel and Casgevy. BEAM-101's efficient manufacturing process allows for fewer mobilization cycles, with an average of 1.4 cycles, compared to Reni-cel's 4.6 and Casgevy's 4.7. This efficiency could potentially expand the eligible patient population for gene editing therapies. Additionally, Beam's approach includes a novel conditioning regimen using an anti-CD117 antibody, aiming to reduce toxicity and increase the feasibility of the treatment. The company's stock saw a 6.5% increase following the announcement, reflecting positive market sentiment towards the potential of BEAM-101.
View original story
Similar markets
Meets primary endpoint • 25%
Fails primary endpoint • 25%
Mixed results • 25%
Trial not completed by end of 2025 • 25%
No improvement • 25%
Slight improvement • 25%
Moderate improvement • 25%
Significant improvement • 25%
Yes • 50%
No • 50%
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Data Released • 25%
Positive outcome with significant efficacy • 25%
Mixed outcome with limited efficacy • 25%
Negative outcome with no efficacy • 25%
Trial terminated early due to safety concerns • 25%
